Summary

This article presents the relevant radiographic data for the Efficacy at 24 Weeks and Long-Term Safety, Tolerability, and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) trial [FUTURE 1; NCT01392326]. Analysis specifically focuses on one of the secondary outcomes of the study, radiographic analysis at week 24 (primary analysis) and radiographic analysis at week 52 (secondary analysis).